[go: up one dir, main page]

WO2002081457A1 - Derives d'acide 1,4!-diazepane-1-carboxylique, leur procede de preparation et leur utilisation comme antagonistes des tachykinines - Google Patents

Derives d'acide 1,4!-diazepane-1-carboxylique, leur procede de preparation et leur utilisation comme antagonistes des tachykinines Download PDF

Info

Publication number
WO2002081457A1
WO2002081457A1 PCT/GB2002/001601 GB0201601W WO02081457A1 WO 2002081457 A1 WO2002081457 A1 WO 2002081457A1 GB 0201601 W GB0201601 W GB 0201601W WO 02081457 A1 WO02081457 A1 WO 02081457A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
fluoro
carboxylic acid
diazepane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001601
Other languages
English (en)
Inventor
Guiseppe Alvaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to US10/473,195 priority Critical patent/US7196077B2/en
Priority to EP02720171A priority patent/EP1377558B1/fr
Priority to DE60205600T priority patent/DE60205600T2/de
Priority to JP2002579445A priority patent/JP4336107B2/ja
Priority to AT02720171T priority patent/ATE302195T1/de
Publication of WO2002081457A1 publication Critical patent/WO2002081457A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to diazepine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use.
  • the invention relates to novel compounds, which are antagonists of tachykinins, including substance P and other neurokinins.
  • Tachykinins are a family of peptides that share a common carboxyl-terminal sequence (Phe- X-Gly-Leu-Met-NH2). They are actively involved in the physiology of both lower and advanced lifeforms. In mammalian lifeforms the main tachykinins are subtance P (SP),
  • NKA Neuro nin A
  • NKB NeuroMnin B
  • NKA-preferring and NK3 (TSIKB-preferring) which are widely distributed throughout the central nervous (CNS) and peripheral nervoiis system.
  • R represents hydrogen or Ci .4 alkyl
  • Ri represents hydrogen or Cj_4 alkyl
  • R2 represents trifluoromethyl, i-4 alkyl, Cj_4 alkoxy, trifluoromethoxy or halogen;
  • R3 represents halogen or Cj_4 alkyl
  • R4 represents hydrogen, halogen, Cj ⁇ j. alkyl or C(0)Rg;
  • R5 represents hydrogen, C ⁇ alkyl or R5 together within the Ri represents C3.7 cycloalkyl;
  • Rg represents hydroxy, amino, methylamino, dimethylamino, 5 membered heteroaryl group containing 1 to 3 heteroatoms selected independently from oxygen, sulphur and nitrogen or a
  • X and Y are independently NR ⁇ or methylene; R7 represents hydrogen, C ⁇ _ alkyl or C3.7 cycloalkyl; provided that when X is NRy,Y is methylene and when X is methylene, Y is NR7. and pharmaceutically acceptable salts and solvates thereof.
  • a further embodiment of the invention provides compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof wherein
  • R represents hydrogen or C .4 alkyl
  • Ri represents hydrogen or Ci .4 alkyl
  • R2 represents trifluoromethyl, C ⁇ alkyl, C ⁇ _4 alkoxy, trifluoromethoxy or halogen
  • R3 represents halogen or Ci .4 alkyl
  • R4 represents hydrogen, halogen or a C ⁇ alkyl group
  • R5 represents hydrogen; m or n are independently zero or an integer from 1 to 3;
  • X and Y are independently NR7 or methylene
  • R7 represents hydrogen, Ci .4 alkyl or C3_7 cycloalkyl; provided that when X is NR7 ,Y is methylene and when X is methylene,Y is NR7; and pharmaceutically acceptable salts and solvates thereof.
  • Suitable pharmaceutically acceptable salts of the compounds of general formula (T) include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids, for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, trifluoroacetates, acetates, citrates, succinates, tartrates, fumarates and maleates.
  • pharmaceutically acceptable organic or inorganic acids for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, trifluoroacetates, acetates, citrates, succinates, tartrates, fumarates and maleates.
  • the solvates may, for example, be hydrates.
  • references hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable acid addition salts and their pharmaceutically acceptable solvates.
  • the wedge bond indicates that the bond is above the plane of the paper.
  • the broken bond indicates that the bond is below the plane of the paper.
  • Cj ⁇ alkyl refers to a straight or branched alkyl group containing from 1 to 4 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-buryl, isoburyl, tert-butyl, 1 methylethyl or 2-methyl propyl.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • Cj_4 alkoxy group may be a straight chain or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy.
  • C3_7 cycloalkyl group means a non aromatic monocyclic hydrocarbon ring of 3 to 7 carbon atom such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • 5 or 6 membered heteroaryl group includes furanyl, thiophenyl, pyrrolyl, i idazolyl, thiazolyl, oxazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3- triazolyl, 1,2,3-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4- thiadiazolyl, 1,2,5-oxadiazolyl, 1,2,5-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4 oxadiazolyl, 1,2,5-triazinyl or 1,3,5-triazinyl and the like.
  • the group R4 may be in position 3, 5, 6, 7 of the diazepine ring;
  • the group R4 may be in position 2, 3, 5, 6 of the diazepine ring.
  • R is preferably hydrogen or methyl .
  • Rl is preferably hydrogen or methyl
  • n is preferably an integer from 1 to 2.
  • R3 is preferably halogen (e.g. fluorine) and/or a C _4 alkyl (e.g. methyl) group and m is preferably an integer from 1 to 2.
  • R4 is preferably hydrogen, halogen (e.g. fluorine), methyl or C(0)Rg .
  • R5 is preferably hydrogen, methyl or together with Rj is cyclopropyl.
  • R is preferably amino, methylamino or dimethylamino.
  • R7 is preferably hydrogen, methyl or cyclopropyl.
  • a preferred class of compounds of formula (I) is that wherein the chiral atom indicated as * is in ⁇ configuration.
  • m is conveniently 2 and within these compounds those wherein the groups R3 are at the 2 and the 4 position of the phenyl ring are preferred.
  • a further preferred class of compounds of formula (I) is that wherein R2 is trifluoromethyl and/or halogen (i.e chlorine or fluorine), R3 is halogen (e.g. fluorine) and C1 alkyl (e.g. methyl) group at the 2 and the 4 position of the phenyl ring, X is NH2 and Y is methylene or Y is NH2 and X is methylene, Rj is a methyl or hydrogen, R is methyl, R5 and R4 are hydrogen m is 2 and n is 1 or 2.
  • R2 is trifluoromethyl and/or halogen (i.e chlorine or fluorine)
  • R3 is halogen (e.g. fluorine) and C1 alkyl (e.g. methyl) group at the 2 and the 4 position of the phenyl ring
  • X is NH2 and Y is methylene or Y is NH2 and X is methylene
  • Rj is
  • Preferred compounds according to the invention are: 2-(S)-(4-Fluoro-2-methyl-phenyl)-[l,4]-diazepane-l-carboxylic acid, (3,5-bis- trifluoromethyl-benzyl)-methylamide;
  • the compounds of the invention are antagonists of tachykinins, including substance P and other neurokinins, both in vitro and in vivo and are thus of use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
  • the compounds of the present invention may also have activity as serotonin reuptake inhibitors.
  • NKi-receptor binding affinity has been determined in vitro by the compounds' ability to displace [3H]-substance P (SP) from recombinant human N i receptors expressed in Chinese Hamster Ovary (CHO) cell membranes.
  • CHO cell membranes were prepared by using a modification of the method described by Dam T and Quirion R Q?eptides, 7: 855-864, 1986).
  • ligand binding was performed in 0.4 mL of 50 mM HEPES, pH 7.4, containing 3 mM MnCl 2 , 0.02% BSA, 0.5 nM [ 3 H]- Substance P (30 ⁇ 56 Ci/mmol, Amersham), a final membrane concentration of 25 ⁇ g of protein/ml, and the test compounds.
  • the incubation proceeded at room temperature for 40 min.
  • Non-specific binding was determined using excess of Substance P (1 ⁇ M) and represents about 6% of the total binding.
  • CDP-DAG cytidinediphosphodiacylglycerol
  • PLC phospholipase C
  • the action of the compounds of the invention at the NKi receptor may be determined by using conventional tests.
  • the ability to bind at the NK receptor was determined using the gerbil foot tapping model as described by Rupniak & Williams, Eur. J. of Pharmacol., 1994.
  • Human Serotonin Transporter (hSERT) binding affinity has been determined in vitro by the compounds' ability to displace [ 3 H]-lmipramine from human serotonin transporter expressed in Human Embryonic Kidney HEK293 cell membranes (Receptor Biology Inc.).
  • 4 nM of [ 3 Hj-lmipramine (703 GBq/mmol, Amersham) were incubated with 0.02 mg/ml of cell membrane and the compound to be tested at different concentrations (7 concentration points) in 50 mM Tris HC1, pH 7.5, 120 mM of NaCl and 5 mM KC1.
  • the reaction was performed for 60 min at 4°C and was terminated by filtration through GF/B U ifilters 96 wells/case (presoaked in 0.5 % PEI) using a Cell Harvester (Packard). Scintillation fluid was added to each filtered spot and radioactivity was determined using a scintillation counter (TopCount (Packard)). Non-specific binding was determined using Imipramine (lOO ⁇ M) and represents about 5% of the total binding. Competition experiments were conducted with duplicate determination for each point. Msat601 software package was used to elaborate the competition binding data. IC 50 values were converted to K ; values using Cheng-Prusoff equation.
  • Compounds of the invention are useful in the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and /or in the treatment of anxiety.
  • Depressive states include major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, the treatment of anxiety and the treatment of panic disorders.
  • Major depressive disorders include dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidme, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood.
  • Major depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.
  • Compounds of the invention are useful as analgesics. Li particular they are useful in the treatment of traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain; various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment
  • Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadianrudic disorders.
  • Cognitive disorders include dementia, amnestic disorders and cognitive disorders not otherwise specified.
  • compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and or memory deficit.
  • Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds), or in the treatment of tolerance to and dependence on opiates (e.g. cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative ipnotic, amphetamine or amphetamine- related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.
  • opiates e.g. cannabis, heroin, morphine
  • benzodiazepines e.g. cocaine, sedative ipnotic, amphetamine or amphetamine- related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.
  • Compounds of the invention are also useful as anti-inflammatory agents. In particular they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.
  • Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.
  • Emesis i.e. nausea, retching and vomiting.
  • Emesis includes acute emesis, delayed emesis and anticipatory emesis.
  • the compounds of the invention are useful in the treatment of emesis however induced.
  • emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g.
  • cytarabine methotrexate and 5- fluorouracil
  • vinca alkaloids e.g. etoposide, vinblastine and vincristine
  • others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof
  • radiation sickness e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g.
  • gastritis or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intercranial pressure; decreased intercranial pressure (e.g.
  • opioid analgesics such as mo ⁇ hine
  • gastro-oesophageal reflux disease acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.
  • Compounds of the invention are also useful in the treatment of gastrointestinal disorders such as irritable bowel syndrome; skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorrhage; f ⁇ brosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and rheumatic diseases such as fibrositis; and cough.
  • gastrointestinal disorders such as irritable bowel syndrome
  • skin disorders such as psoriasis, pruritis and sunburn
  • vasospastic diseases such as angina, vascular headache and Reynaud's disease
  • cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorr
  • the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.
  • a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
  • a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
  • a method for the treatment of a mammal including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and formulated for administration by any convenient route.
  • a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and formulated for administration by any convenient route.
  • Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • compounds of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • the composition may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non- aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • a proposed dose of the compounds of the invention is 1 to about lOOOmg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian.
  • the dosage will also depend on the route of administration and the particular compound selected. Thus for parenteral administration a daily dose will typically be in the range of 1 to about 100 mg, preferably 1 to 80 mg per day. For oral administration a daily dose will typically be within the range 1 to 300 mg e.g 1 to 100 mg.
  • the reduction is carried out with a suitable metal reducing agent such as a metal hydride, at a temperature within the range of room temperature to the reflux temperature of the reaction mixture.
  • a suitable metal reducing agent such as a metal hydride
  • the reaction conveniently takes place in an aprotic solvent such as dicholoromethane, 1,2 dichloroethane, acetone, or an ether such as tetrahydrofuran.
  • an aprotic solvent such as dicholoromethane, 1,2 dichloroethane, acetone, or an ether such as tetrahydrofuran.
  • suitable metal hydrides for this reaction include borane hydride, alane hydride or a metal hydride complex like lithium aluminium hydride or sodium borohydride, or an organometallic complex such as borane-methyl sulphide, 9-borabicyclononane (9-BBN), triethylsilane, sodium triacetoxyborohydride, sodium cyanoborohydride.
  • suitable solvents for the reaction are ether (e.g. tetrahydrofuran), or halohydrocarbon (e.g. dichloromethane) or an amide (e.g. N,N-dimethylformamide).
  • reaction in the presence of tosyl chloride and an inorganic base such as sodium carbonate.
  • the reaction may be carried out in an aprotic organic solvent such as acetone, at a temperature within the range of room temperature to the reflux temperature of the reaction mixture.
  • the oximes (TV) and (V) may be prepared by treating compounds of formula (VT)
  • hydroxylamine in a protic solvent such as methanol.
  • Compounds of formulae (H) or (Tfl) wherein R7 is Ci .4 alkyl or C3.7 cycloalkyl may be prepared from compounds of formulae (U) or (ID) wherein R5 is hydrogen by reaction with an alkylating agent R7X wherein X is a suitable leaving group such chloride, bromide, triflate, mesylate or tosylate.
  • Compounds of formula (VI) may be prepared by treating tetrahydro-4-pyridone compounds of formula (VTJ)
  • VflT intermediate carbonyl chloride
  • reaction conveniently take place in an aprotic solvent such as a hydrocarbon, a halohydrocarbon such as dichloromethane or an ether such as tetrahydrofuran optionally in the presence of a base such as a tertiary amine e.g. diisopropylethylamine.
  • aprotic solvent such as a hydrocarbon, a halohydrocarbon such as dichloromethane or an ether such as tetrahydrofuran
  • a base such as a tertiary amine e.g. diisopropylethylamine.
  • a compound formula (I) as a salt thereof, for example a pharmaceutically acceptable salt
  • this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate amount of suitable acid and in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tefrahydrofuran).
  • a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tefrahydrofuran).
  • Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compound of formula (I) using conventional methods.
  • the compounds of formula (1) may readily be isolated in association with solvent molecules by crystallisation from or evaporation of an appropriate solvent to give the corresponding solvates.
  • enantiomers of a compound of general formula (I) may be synthesised from the appropriate optically active intermediates using any of the general processes described herein.
  • the required enantiomer may be prepared by the corresponding chiral tetrahydro-4-pyridone of formula (VH) using any of the processes described above for preparing compounds of formula (I) from compounds of formula (NTT).
  • the chiral compounds (VTI) may be prepared from the corresponding racemic (VH) using conventional procedures such as salt formation with a suitable optically active acid, separating the resultant diastereoisomeric salts by conventional means e.g. chromatography and crystallisation followed by hydrolysis of the diastereoisomeric salts.
  • a suitable optically active acid for use in the process is L-(+)-mandelic acid.
  • the enantiomers of the compound of formula (LX) may be prepared by reaction of a chiral amine (LX) using any of the process described above for preparing compounds of formula (VH) from amine (LX).
  • the chiral amine (LX) may be prepared from the corresponding racemic amine (VH) using any conventional procedures such as salt formation with a suitable optically active acid.
  • a suitable optically active acid for use in the process is L-(+)-mandelic acid.
  • Infrared spectra were measures in chloroform or nujol solutions on a FT-IR instrument.
  • Proton Magnetic Resonance ( ⁇ MR) spectra were recorded on Varian instruments at 400 or
  • T.l.c. refers to thin layer chromatography on 0.25 mm silica gel plates (60F-254 Merck) and visualized with UN light. Solutions were dried over anhydrous sodium sulphate.
  • Method A A solution of triphosgene (147 mg) dissolved in dry DCM (5 mL) was added to a solution of intermediate 2 (250 mg) and DIPEA (860 ⁇ L) in dry DCM (15 mL) previously cooled to 0°C under a Nitrogen atmosphere. After 2 hours, a solution of [l-(S)-(3,5-bis-trif ⁇ uoromethyl- phenyl)-ethyl]-methylamine hydrochloride (510 mg) and DIPEA (320 ⁇ L) in dry acetonitrile (20 mL) was added and the mixture was heated to 70°C for 16 hour.
  • T.l.c CH/THF/toluene 7:2:1, RfM).56.
  • the mixture was stirred at r.t. 6 hours, then it was filtered over celite washing with DCM.
  • Example 12b Compound 2 (64 mg) was dissolved in dry Et z O (1.5 mL) and treated with hydrochloric acid
  • the active ingredient is blended with the other excipients.
  • the blend can be used to fill gelatin capsules or compressed to form tablets using appropriate punches.
  • the tablets can be coated using conventional techniques and coatings.
  • the active ingredient is blended with lactose, microcrystalline cellulose and part of the croscarmellose sodium.
  • the blend is granulated with povidone after dispersing in a suitable solvent (i.e. water).
  • a suitable solvent i.e. water
  • the granule, after ⁇ drying and comminution is blended with the remaining excipients.
  • the blend can be compressed using appropriate punches and the tablets coated using conventional techniques and coatings.
  • the formulation may be packed in glass ampoules or vials and syringes with a rubber stopper and a plastic/metal overseal (vials only).
  • the formulation may be packed in glass vials or plastic bag.
  • the affinity of the compound of the invention for NK1 receptor was determined using the NK j -receptor binding affinity method measuring in vitro by the compounds' ability to displace [3H] - substance P (SP) from recombinant human NKi receptors expressed in Chinese Hamster Ovary (CHO) cell membranes.
  • SP displace [3H] - substance P
  • the affinity values are expressed as negative logarithm of the inhibition constant (Ki) of displacer ligands (pKi).

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des dérivés de diazépine de formule (I), dans laquelle R représente hydrogène ou alkyle en C1-4 ; R1 représente hydrogène ou alkyle en C1-4 ; R2 représente trifluorométhyle, alkyle en C1-4, alcoxy en C1-4, trifluorométhoxy ou halogène ; R3 représente halogène ou alkyle en C1-4 ; R4 représente hydrogène, halogène, alkyle en C1-4 ou COR6 ; R5 représente hydrogène, alkyle en C1-4 ou R5 conjointement avec R1 représente cycloalkyle en C3-7 ; R6 représente hydroxy, amino, méthylamino, diméthylamino, un groupe hétéroaryle à 5 chaînons contenant 1 à 3 héteroatomes sélectionnés, indépendamment les uns des autres, parmi oxygène, soufre et azote ou un groupe hétéroaryle à 6 chaînons contenant 1 à 3 atomes d'azote ; m ou n sont, indépendamment l'un de l'autre, zéro ou un nombre entier de 1 à 3 ; X et Y représentent, indépendamment l'un de l'autre, NR7 ou méthylène ; dans la mesure où si X représente NR7, Y signifie méthylène et si X représente méthylène, Y signifie NR7 ; R7 représente hydrogène, alkyle en C1-4 ou cycloalkyle en C3-7. Cette invention concerne également des sels ou solvates pharmaceutiquement acceptables desdits dérivés, un procédé pour leur préparation et leur utilisation dans le traitement de pathologie induite par les tachykinines.
PCT/GB2002/001601 2001-04-05 2002-04-05 Derives d'acide 1,4!-diazepane-1-carboxylique, leur procede de preparation et leur utilisation comme antagonistes des tachykinines Ceased WO2002081457A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/473,195 US7196077B2 (en) 2001-04-05 2002-04-05 Tachykinin antagonists
EP02720171A EP1377558B1 (fr) 2001-04-05 2002-04-05 Derives de l'acide [1,4]-diazepane-1-carboxylique, leur procede de preparation et leur utilisation comme antagonistes des tachykinines
DE60205600T DE60205600T2 (de) 2001-04-05 2002-04-05 [1,4]-diazepane-1-carbonsaüre derivate, herstellungsverfahren und verwendung als tachykinin antagonisten
JP2002579445A JP4336107B2 (ja) 2001-04-05 2002-04-05 ［１，４］−ジアゼパン−１−カルボン酸誘導体、それらの製造方法およびタキキニンアンタゴニストとしてのそれらの使用
AT02720171T ATE302195T1 (de) 2001-04-05 2002-04-05 (1,4)-diazepane-1-carbonsaüre derivate, herstellungsverfahren und verwendung als tachykinin antagonisten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0108595.0 2001-04-05
GBGB0108595.0A GB0108595D0 (en) 2001-04-05 2001-04-05 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2002081457A1 true WO2002081457A1 (fr) 2002-10-17

Family

ID=9912333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001601 Ceased WO2002081457A1 (fr) 2001-04-05 2002-04-05 Derives d'acide 1,4!-diazepane-1-carboxylique, leur procede de preparation et leur utilisation comme antagonistes des tachykinines

Country Status (8)

Country Link
US (2) US7196077B2 (fr)
EP (1) EP1377558B1 (fr)
JP (1) JP4336107B2 (fr)
AT (1) ATE302195T1 (fr)
DE (1) DE60205600T2 (fr)
ES (1) ES2243710T3 (fr)
GB (1) GB0108595D0 (fr)
WO (1) WO2002081457A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068427A1 (fr) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Derive de carboxamide et son utilisation
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
WO2013004766A1 (fr) 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
WO2013124286A1 (fr) 2012-02-22 2013-08-29 Leo Pharma A/S Nouveaux composés antagonistes du récepteur de la neurokinine 1
WO2015024878A1 (fr) 2013-08-20 2015-02-26 Leo Pharma A/S Nouveaux composés antagonistes ii du récepteur de la neurokinine 1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045433A (en) * 1974-05-29 1977-08-30 Richter Gedeon Vegyeszeti Gyar Rt. 1,3,4,5-Tetrahydro-2H-1,4-benzodiazepin-2-ones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE19737334A1 (de) 1997-08-27 1999-03-04 Solvay Pharm Gmbh 7-Phenyl-1,4-diazepan-Derivate, sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6719147B2 (en) * 2001-04-27 2004-04-13 The University Of Delaware Supported mesoporous carbon ultrafiltration membrane and process for making the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045433A (en) * 1974-05-29 1977-08-30 Richter Gedeon Vegyeszeti Gyar Rt. 1,3,4,5-Tetrahydro-2H-1,4-benzodiazepin-2-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARMOUR D R ET AL: "1,4-benzodiazepin-2-one derived neurokinin-1 receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 15, 5 August 1997 (1997-08-05), pages 2037 - 2042, XP004136381, ISSN: 0960-894X *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068427A1 (fr) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Derive de carboxamide et son utilisation
JPWO2005068427A1 (ja) * 2004-01-14 2007-09-06 武田薬品工業株式会社 カルボキサミド誘導体およびその用途
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
WO2013004766A1 (fr) 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
WO2013124286A1 (fr) 2012-02-22 2013-08-29 Leo Pharma A/S Nouveaux composés antagonistes du récepteur de la neurokinine 1
US9181259B2 (en) 2012-02-22 2015-11-10 Leo Pharma A/S Substituted pyrrolo[1,2-a]piperazines and pyrrolo[1,2-a][1,4]diazepines as neurokinin 1 receptor antagonists
WO2015024878A1 (fr) 2013-08-20 2015-02-26 Leo Pharma A/S Nouveaux composés antagonistes ii du récepteur de la neurokinine 1

Also Published As

Publication number Publication date
JP4336107B2 (ja) 2009-09-30
US20070135414A1 (en) 2007-06-14
EP1377558A1 (fr) 2004-01-07
US20040127485A1 (en) 2004-07-01
US7196077B2 (en) 2007-03-27
GB0108595D0 (en) 2001-05-23
ES2243710T3 (es) 2005-12-01
EP1377558B1 (fr) 2005-08-17
ATE302195T1 (de) 2005-09-15
DE60205600D1 (de) 2005-09-22
DE60205600T2 (de) 2006-02-09
JP2004526753A (ja) 2004-09-02

Similar Documents

Publication Publication Date Title
EP1921064B1 (fr) Composition pharmaceutique
EP1218359B1 (fr) Derives de piperazine utilises comme antagonistes de tachykinines
AU2001295723A1 (en) Chemical compounds
NZ533785A (en) Piperidine derivatives their preparation and their use in the treatment of condition mediated by tachykinins
WO2003066621A1 (fr) Derives de piperidine et leur utilisation en tant qu'antagonistes des tachykinines
US20070135414A1 (en) Tachykinin Antagonists
HK1058788B (en) Chemical compounds
HK1118554A (en) Pharmaceutical composition
HK1103398A (en) Pharmaceutical composition
HK1075889B (en) Pharmaceutical composition
HK1072251B (en) Piperidine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002720171

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002579445

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002720171

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10473195

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002720171

Country of ref document: EP